More

    India’s COVAXIN, Now Hungarian GMP Certified

    Bharat Biotech’s COVAXIN achieved another big milestone today. The Made in India COVID19 vaccine COVAXIN®️ has received a certificate of Good Manufacturing Practice (GMP) compliance from the Hungarian authorities.

    The approval received is from the National Institute of Pharmacy and Nutrition Hungary certifying the GMP for the manufacture of COVAXIN®️. The certificate of GMP is now listed on the EudraGMDP database, which is the database of the European Community of manufacturing authorizations and certificates of the good manufacturing practice.

    Bharat Biotech intends to submit documentation for Emergency Use Authorization (EUA) in several additional countries worldwide.

    With this approval, Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at global quality standards and moving forward in the ongoing fight against the Covid-19 pandemic. The recognition complements our commitment of driving world-class innovation and being a frontrunner in the research and development of vaccines.

    COVAXIN manufacturing news update

    Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in India, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial.

    Covaxin demonstrated 77.8 per cent effectiveness against symptomatic Covid-19 and 65.2 per cent protection against the B.1.617.2 Delta variant, Bharat Biotech had said while concluding the final analysis of Covaxin efficacy from Phase-3 trials on July 3.

    COVAXIN effective against Delta Plus Variant – ICMR Study

    COVAXIN, India’s first indigenous vaccine to fight Covid-19, is effective against the Delta Plus variant of coronavirus, a study conducted by Indian Council of Medical Research (ICMR) has said, according to news agency ANI. Covaxin has been developed by Bharat Biotech, in collaboration with ICMR.

    Delta Plus is a mutated form of the Delta variant, first discovered in India. It is characterised by increased transmissibility. Last week, Union Science and Technology Minister Jitendra Singh said in Parliament that 70 cases of the Delta Plus variant were found by INSACOG, a group of 28 laboratories involved in genome sequencing.

    In July, the Hyderabad-based company released data from the final analysis of Covaxin and said that it demonstrated overall efficacy of 77.8 per cent against symptomatic infection. It also said that Covaxin has now received emergency use authorisations (EUAs) in 16 countries including, Brazil, India, Philippines, Iran, Mexico, with EUAs in process in 50 countries worldwide.

    What is COVAXIN

    COVAXIN®, India’s indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).

    The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) high containment facility.

    The vaccine is developed using Whole-Virion Inactivated Vero Cell derived platform technology. Inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.

    Share

    Latest Updates

    Related Articles

    Anthony Albanese Takes Over as Australia’s New PM, Promises a “journey of change”

    Anthony Albanese, the leader of Australia's Labor Party, was sworn in as the country's...

    French Open: Alcaraz Smashes Out Lorendo to Enter Round Two

    Carlos Alcaraz, a 16-year-old wonder, defeated Argentine lucky loser Juan Ignacio Londero 6-4, 6-2,...

    IPL Record Batsman Shikhar Dhawan bowled out from Team India

    Shikhar Dhawan lost his place in Team India, despite not being selected for the...

    Ankiti Bose Sacked by Zilingo on Charges of Financial Wrong Doing

    Ankiti Bose, Zilingo's co-founder and CEO, has been sacked after the company's board suspended...